VYCOR MEDICAL INC (VYCO): Results of Operations and Financial Condition
VYCOR MEDICAL INC (VYCO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Vycor Medical Releases Financial Results for the Three And Six Months Ended June 30, 2026 BOCA RATON, FL (August 14, 2026) – Vycor Medical, Inc. (“Vycor”) (OTCQB—VYCO), today announced financial results for the three and six months ended
How this was made
The 30-second read
Why it matters
Traders can use the disclosed revenue contraction and operating profit deterioration to update near-term expectations for VBAS commercialization, while separately weighing the potential longer-term credibility boost from additional peer-reviewed clinical publications.
Market read
The primary tradable takeaway is the disclosed year-over-year decline in revenue and operating profit for both the quarter and first half of 2026, with international markets driving most of the drop.
What to watch
The filing highlights new peer-reviewed VBAS studies (53 total papers), which could support longer-term adoption even as near-term financials weaken.
Background
This SEC 8-K (Item 2.02) reports Vycor Medical’s financial results for the three and six months ended June 30, 2026, including GAAP and non-GAAP operating metrics and division revenue.
Ticker impact
Vycor Medical reported 3-month revenue of $418,264, down 16% year over year, with GAAP operating profit falling to $6,851.
Near-term downside bias as traders reprice weak top-line and operating profitability trends, especially given the international-market decline.
The filing provides specific GAAP and non-GAAP operating profit declines and revenue contraction for both the quarter and six-month period, which typically pressures microcap sentiment and liquidity.
Market effects
Signals ongoing commercialization pressure for neurosurgical device revenue, with international sales volatility affecting quarterly comparability.
International markets are cited as the main driver of the quarterly revenue decline, implying regional demand softness.
Limited broader market impact expected given the company size and OTCQB listing.
Counterpoint
International sales are described as lumpy, so the quarter’s decline may not reflect sustained demand if large orders shift into later periods.
Key entities
- companyVYCOR MEDICAL, INC.
OTCQB-listed medical device company reporting quarterly and six-month financial results for VBAS and NovaVision.
- productViewSite Brain Access System (VBAS)
Primary revenue-generating system for neurosurgeons; revenue declined year over year in the reported periods.
- business_unitNovaVision
Business in development with small but slightly higher revenue year over year.
